Abeona Therapeutics Inc. (NASDAQ:ABEO) has been assigned a $14.00 price objective by analysts at Maxim Group in a report released on Wednesday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective points to a potential upside of 132.95% from the company’s current price.
Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 15th. FBR & Co set a $15.00 price target on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 18th. Finally, Rodman & Renshaw reissued a “buy” rating and issued a $17.00 price target on shares of Abeona Therapeutics in a research report on Friday, August 5th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $14.00.
Shares of Abeona Therapeutics (NASDAQ:ABEO) traded up 14.48% during trading on Wednesday, hitting $6.88. The stock had a trading volume of 536,026 shares. The stock’s market cap is $230.79 million. The stock’s 50-day moving average price is $5.00 and its 200 day moving average price is $3.33. Abeona Therapeutics has a one year low of $2.05 and a one year high of $7.00.
Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. On average, equities analysts forecast that Abeona Therapeutics will post ($0.73) EPS for the current year.
In other news, Director Todd Wider acquired 5,000 shares of the company’s stock in a transaction dated Tuesday, September 20th. The stock was bought at an average price of $5.48 per share, with a total value of $27,400.00. Following the completion of the acquisition, the director now owns 75,000 shares in the company, valued at approximately $411,000. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 13.00% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares during the last quarter. BlackRock Fund Advisors raised its stake in Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 23,734 shares during the last quarter. Sabby Management LLC raised its stake in Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares during the last quarter. Finally, Royce & Associates LP raised its stake in Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares during the last quarter. 19.95% of the stock is owned by institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.